Up to one-third of all new asthma cases each year are attributed to the harmful air pollutants that are emitted by ...
The long-term safety and efficacy of omalizumab, alongside promising phase 3 trial results that demonstrated the efficacy and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback